Merck's anti-TL1A antibody shows benefit in hidradenitis suppurativa but misses endpoint in rare lung disease trial

Merck reported mixed results from its anti‑TL1A antibody, a product of its $10.8 billion acquisition of Prometheus Biosciences.

In a mid‑stage study for hidradenitis suppurativa, the antibody met its primary efficacy endpoint, indicating a potential new treatment option for the chronic skin condition.

Conversely, the same molecule failed to achieve its primary endpoint in a separate mid‑stage trial for systemic sclerosis‑associated interstitial lung disease, a rare and serious lung disorder.

The divergent outcomes highlight the antibody’s disease‑specific activity and suggest further development will focus on the skin indication while the lung program may be reconsidered.